Drugs / PollenVax
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07317960 | Nov 2025 → Jan 2026 | allergic rhinitis | Kazakh National Agrarian University | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07563439 | May → Sep 2026 overdue | allergic rhinitis | Kazakh National Agrarian University | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PollenVax | “PollenVax is a subcutaneous allergen-specific immunotherapy (SCIT) emulsion consisting of recombinant major mugwort pollen allergen Art v 1 combined with oil-in-water adjuvant...” NCT07563439 ↗ |
| Modality | Vaccine | “recombinant allergen-based vaccine” NCT07317960 ↗ |
| Route | Subcutaneous | “administered subcutaneously” NCT07317960 ↗ |